Pioneers in Neuroscience

1 August 2022

New treatment for Multiple Sclerosis becomes widely available in Australia

From 1 August 2022, VUMERITY^TM (diroximel fumarate), a new oral treatment for a form of multiple sclerosis (MS) called relapsing-remitting MS (RRMS), will be available on the Pharmaceutical Benefits Scheme (PBS).¹

SPINRAZA becomes first available treatment on the Pharmaceutical Benefits Scheme for adults living with Spinal Muscular Atrophy

From 1 August 2022, adults (at least 19 years of age or older) with 5q Spinal Muscular Atrophy (SMA) and symptom onset prior to their 19^th birthday will be able to access SPINRAZA^® (nusinersen) on the Pharmaceutical Benefits Scheme (PBS),¹ the first and only reimbursed treatment for this patient population in Australia.²

When Scott was 59 years old, he and his wife Jill began noticing some changes in his cognition. Scott was struggling to find the right words in conversations and was having difficulties problem solving and remembering names.

Three years after he first experienced symptoms, Scott was diagnosed with Alzheimer's dementia.

A new report from the University of Canberra’s National Centre for Social and Economic Modelling (NATSEM) reveals the staggering future economic cost of Alzheimer's disease, and its impact on Australia’s workforce, patients, families and communities.

This report expands on NATSEM and Dementia Australia’s Economic Cost of Dementia in Australia 2016-2056 Report released in 2017 and projects a 20-year $442 billion impact to the Australian economy.

As the most common form of dementia, AD currently affects approximately 330,000 Australians and is a major cause of death and disability.

There is a window of opportunity in Australia to prepare for the potential introduction of disease-modifying therapies (DMTs) for this devastating disease.

After 20 years in Australia and 15 in New Zealand, Biogen remains steadfast in its commitment to work fearlessly to change lives. Biogen Australia and New Zealand is proud to have highly motivated and engaged people with a strong commitment to patients. A strong culture of inclusion and diversity empowers Biogen’s people to make a positive impact on the communities they serve.

Matilda’s story: Living with Spinal Muscular Atrophy

Matilda is a busy four-year-old. Like most children of her age, she wants to do everything herself but due to living with Spinal Muscular Atrophy (SMA) sometimes Matilda needs a little extra help.

Stephen’s story: Living with Multiple Sclerosis

Stephen was 22 years old when he was diagnosed with Multiple Sclerosis (MS), a life-long autoimmune disease that damages the central nervous system (CNS). Over time, damage to the CNS can cause physical disability and impair neurological functions like motor skills, thinking and vision.

Biogen Australia is exceptionally proud to announce that it has been recognised as a 2021 Great Place to Work, demonstrating that the challenges posed by the pandemic and remote working have not affected the company’s “vibrant and resilient culture.”

Science that transforms patient lives. Science that seeks to solve societal problems. Science that acts with purpose. Science that is inspired by the diversity and passion of our people. Discover where science meets humanity at Biogen.

June 15, 2021

TO PATIENTS, HEALTHCARE PROVIDERS, PARTNERS, AND OUR COMMUNITY

Since the early days of the pandemic, employee safety and well-being have been a top priority for Biogen. We have put in place very clear measures aimed at maintaining critical work so that we can continue delivering lifesaving medicines to people around the world. 

In an unprecedented year, Biogen continued to accelerate action on key challenges of our time including equity and access, diversity and inclusion and climate and health. Read about our progress on advancing environmental, social and governance (ESG) priorities, and our goals for a healthier, more resilient and equitable future.

September 1, 2020

This SMA Awareness month, Dylan Alcott is calling for fellow trailblazers from the adult SMA community 

At Biogen, our mission is clear: we are pioneers in neuroscience.

View our Biogen ANZ Corporate Brochure

Level 4, 2 Banfield Road
Macquarie Park NSW 2113
Australia
Phone: +61 2 8875 3900
Fax: +61 2 9889 1162

Email: enquiriesaunz@biogen.com

Directions

We work together to bring life-changing therapies to patients every day. Start here to find the fulfilling career opportunity that’s right for you.

Biogen is committed to meeting all global transparency requirements. As is our obligation, we record all transfers of value to healthcare professionals and organizations and report pursuant to the applicable local codes and laws.